Can three years of amiodarone therapy cause positive perinuclear anti‑neutrophil cytoplasmic antibody (p‑ANCA) and myeloperoxidase (MPO) positivity, and is amiodarone indicated for non‑obstructive cardiomyopathy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Amiodarone Cause Positive p-ANCA and MPO Positivity?

Yes, amiodarone can cause positive p-ANCA and MPO positivity after 3 years of therapy, though this is not a commonly recognized adverse effect in the standard monitoring guidelines. While drug-induced ANCA-positive vasculitis is well-documented with hydralazine and propylthiouracil, amiodarone is not listed among the primary culprit medications 1.

Evidence for Drug-Induced ANCA Positivity

The strongest evidence examining drug-associated ANCA comes from a study of 30 patients with the highest titers of anti-MPO antibodies, where 33% had been exposed to hydralazine, 10% to propylthiouracil, and 17% to other drugs including penicillamine, allopurinol, and sulfasalazine 1. Notably, amiodarone was not identified as a causative agent in this cohort, suggesting it is either a rare cause or not a recognized trigger for ANCA-positive vasculitis.

However, p-ANCA positivity can occur in various systemic autoimmune diseases without specific MPO reactivity. In a study of 82 p-ANCA-positive sera, MPO specificity was found in only 50% of vasculitis patients, while in other autoimmune conditions, p-ANCA mostly involved unknown autoantigens 2. This indicates that p-ANCA positivity does not always equate to MPO-specific disease.

Clinical Significance

If your patient has developed p-ANCA and MPO positivity while on amiodarone:

  • Consider alternative causes first: Look for signs of ANCA-associated vasculitis (renal involvement, pulmonary hemorrhage, constitutional symptoms)
  • Evaluate for amiodarone's known adverse effects: Pulmonary toxicity (occurs in 1-17% of patients), thyroid dysfunction (hypothyroidism 6%, hyperthyroidism 0.9-2%), and hepatotoxicity 3
  • Distinguish between asymptomatic serologic findings and clinical disease: P-ANCA positivity alone without vasculitic manifestations may not require amiodarone discontinuation

The standard amiodarone monitoring protocol does not include ANCA testing 4. Required monitoring includes thyroid studies, liver transaminases every 6 months, chest radiograph, and pulmonary function tests if pulmonary toxicity is suspected 4.

Is Amiodarone Indicated for Non-Obstructive Cardiomyopathy?

No, amiodarone is not indicated for non-obstructive cardiomyopathy per se. The FDA-approved indication is strictly for life-threatening ventricular arrhythmias 4. However, there are specific scenarios where amiodarone may be appropriate:

Appropriate Uses in Cardiomyopathy Patients:

  • Ventricular arrhythmias: If the patient has survived sustained ventricular tachyarrhythmias, particularly with left ventricular dysfunction, amiodarone is the antiarrhythmic of choice 4
  • Atrial fibrillation with structural heart disease: Amiodarone is recommended as a second-line agent for long-term treatment of atrial fibrillation in patients with structural heart disease 4
  • Heart failure with arrhythmias: In patients with congestive heart failure, amiodarone showed mortality reduction from 24.3% to 19.9% annually (NNT = 23) 4
  • Adjunct to ICD therapy: To reduce frequency of ICD shocks or control atrial fibrillation in highly symptomatic patients 4

Critical Caveats:

ICDs are superior to amiodarone for mortality reduction in high-risk patients with previous myocardial infarction 4. Amiodarone should not be used for primary prevention alone when an ICD is indicated.

For rate-controlled atrial fibrillation in relatively asymptomatic patients on anticoagulation, aggressive rhythm control with amiodarone does not improve outcomes and the toxicity risk is not justified 4.

Practical Recommendation

If your patient with non-obstructive cardiomyopathy has been on amiodarone for 3 years:

  1. Verify the original indication: Was it for documented ventricular arrhythmias, symptomatic atrial fibrillation, or inappropriate use?
  2. If p-ANCA/MPO positive: Evaluate for clinical vasculitis (urinalysis, creatinine, chest imaging, constitutional symptoms)
  3. If no vasculitic disease: The serologic findings alone may not require amiodarone discontinuation if the drug remains indicated for arrhythmia control
  4. If vasculitis is present: Consider amiodarone as a possible (though uncommon) contributor and evaluate risk-benefit of continuation versus alternative antiarrhythmic strategies
  5. Reassess ongoing need: After 3 years, determine if the arrhythmia indication still exists or if amiodarone can be discontinued to eliminate its toxicity burden

The long half-life of amiodarone (averaging 58 days) means effects and potential toxicities persist for months after discontinuation 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.